Q1 Earnings Estimate for DFTX Issued By HC Wainwright

Definium Therapeutics, Inc. (NASDAQ:DFTX) – Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Definium Therapeutics in a report issued on Thursday, April 23rd. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.47) per share for the quarter. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Definium Therapeutics’ current full-year earnings is ($1.97) per share. HC Wainwright also issued estimates for Definium Therapeutics’ Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.44) EPS and Q4 2027 earnings at ($0.19) EPS.

A number of other research analysts also recently issued reports on DFTX. Needham & Company LLC restated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Jefferies Financial Group started coverage on shares of Definium Therapeutics in a research report on Thursday, January 29th. They set a “buy” rating and a $30.00 target price on the stock. Stifel Nicolaus set a $30.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Thursday, April 16th. Royal Bank Of Canada upped their target price on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Finally, Leerink Partners upped their target price on shares of Definium Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $38.00.

Definium Therapeutics Stock Performance

Definium Therapeutics stock opened at $22.48 on Monday. The company has a current ratio of 6.29, a quick ratio of 6.29 and a debt-to-equity ratio of 0.12. Definium Therapeutics has a 1 year low of $6.03 and a 1 year high of $26.25. The company has a market cap of $2.24 billion, a PE ratio of -10.55 and a beta of 2.44. The company’s 50-day moving average is $19.28 and its two-hundred day moving average is $15.58.

Institutional Trading of Definium Therapeutics

A number of large investors have recently bought and sold shares of the business. Commodore Capital LP increased its stake in Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after purchasing an additional 475,000 shares in the last quarter. Vanguard Group Inc. increased its stake in Definium Therapeutics by 11.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock worth $23,732,000 after purchasing an additional 198,878 shares in the last quarter. Rosalind Advisors Inc. increased its stake in Definium Therapeutics by 78.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after purchasing an additional 330,000 shares in the last quarter. UBS Group AG increased its stake in Definium Therapeutics by 7.3% during the 3rd quarter. UBS Group AG now owns 551,809 shares of the company’s stock worth $6,506,000 after purchasing an additional 37,364 shares in the last quarter. Finally, Orbimed Advisors LLC bought a new stake in Definium Therapeutics during the 3rd quarter worth approximately $4,337,000. 27.91% of the stock is owned by institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.